Nexgenia
Nexgenia, based in Seattle, creates stimuli-responsive polymers and nanoparticles for enhanced molecular separations and sensitive immunoassays.
Founded
2011Nexgenia, based in Seattle, creates stimuli-responsive polymers and nanoparticles for enhanced molecular separations and sensitive immunoassays.
Nexgenia, founded in Seattle, focuses on developing and manufacturing proprietary stimuli-responsive polymers and polymer-containing magnetic nanoparticles. These innovative materials change state in response to environmental factors such as temperature, pH, and salt, enabling enhanced molecular separations and sensitive immunoassays. Nexgenia's core mission is to revolutionize the fields of molecular diagnostics and therapeutic research by providing advanced tools that improve efficiency and accuracy.
Notable affiliations include Barrett J. Nehilla, a Senior Scientist at Nexgenia, who has contributed significantly to the field through publications in reputable journals. The company has received a Phase SBIR grant from the National Institute of Allergy and Infectious Disease (NIAID) and collaborates with Seattle Children’s Research Institute to advance immunotherapy research. These achievements underscore Nexgenia's impact on scientific research and its potential to drive innovation in medical diagnostics and treatments.
Companies similar to Nexgenia include Nvigen, Nexgen Forensic Sciences, NeXtGen Biologics and Nektar Therapeutics.
Nexgenia was founded in 2011.
Nexgenia's headquarters is located in Seattle, WA, US.
Nexgenia's most recent funding round was for $1.9M (USD) in August 2016.
As of Aug 19, 2016, Nexgenia has disclosed funding of $3.5M (USD). Undisclosed round amounts are excluded.
Nexgenia has 3 employees as of Feb 5, 2024.
nektar.com
